BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

The Medicines Company 

8 Sylvan Way

Parsippany  New Jersey  07054  U.S.A.
Phone: 973-290-6000 Fax: 973-656-9898


SEARCH JOBS

View Clinical Trials from BioPharm Insight




The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.



 Key Statistics


Email: contactus@themedco.com
Ownership: Public

Web Site: The Medicines Company
Employees: 500+
Symbol: MDCO
 





Collaborations

UCB, Inc.  Contract manufacturing of Bivalirudin peptide active ingredient

Alnylam 





 Company News
The Medicines Company (MDCO) To Announce First Quarter Financial Results On Tuesday, May 5, 2015 4/21/2015 11:38:29 AM
The Medicines Company (MDCO) Release: FDA Approves New Formulation Of MINOCIN (Minocycline) For Injection 4/20/2015 11:17:38 AM
FDA Advisory Committee Recommends Approval Of The Medicines Company (MDCO)'s Antiplatelet Therapy Cangrelor 4/16/2015 5:58:15 AM
The Medicines Company (MDCO) Surges as FDA Panel Approves Once-Rejected Blood Clot Preventer 4/16/2015 5:55:56 AM
The Medicines Company (MDCO) Stock Trading Halted Today 4/15/2015 12:30:07 PM
The Medicines Company (MDCO)’s Kengreal Gets FDA Support After Previous Setbacks 4/13/2015 7:34:13 AM
The Medicines Company (MDCO) Announces Preliminary Worldwide Net Revenue For The First Quarter Of 2015 4/10/2015 11:24:35 AM
The Medicines Company (MDCO) Settles Angiomax (Bivalirudin) Patent Litigation With Sun 4/1/2015 12:20:22 PM
The Medicines Company (MDCO) Receives European Commission (EC) Approval For Three Hospital Acute Care Products: KENGREXAL (Cangrelor), ORBACTIV (Oritavancin) And RAPLIXA(Sealant Powder) 3/30/2015 12:41:14 PM
The Medicines Company (MDCO) Release: Independent Research Confirms Reduction In Mortality And Bleeding Associated With Bivalirudin In High-Risk Acute Coronary Syndrome Patients Undergoing PCI 3/17/2015 11:19:22 AM
12345678910...